Company Overview and News
2018-10-02 investorplace - 1
Will it, or won’t it? Will the yield curve invert, with short-term interest rates pushing their way above long-term interest rates … a relatively rare scenario that’s all too often associated with a troubled economy? It has not happened yet, but as of right now we’re as close to an inverted yield curve as we’ve been in a decade.
AMGN USO VDE O WBA FDX OPRF GLD O87 MRK DG SHY
Scott's Investments provides a free "Dual ETF Momentum" spreadsheet which was originally created in February 2013. The strategy was inspired by a paper written by Gary Antonacci and available on Optimal Momentum. Antonacci's book, Dual Momentum Investing: An Innovative Strategy for Higher Returns with Lower Risk, also details Dual Momentum as a total portfolio strategy.
As yields increase, short-maturity bond funds can offer both higher income potential and a cushion against interest rate risk. Karen Schenone, CFA, explains the mechanics, in part three of her Rising Rates series.
SHV IGSB SHY
2018-08-12 seekingalpha - 7
Dan Loeb's 13F portfolio value increased from $13.32B to $14.35B this quarter. The number of positions decreased from 40 to 38.
ATHTF STZ.B TWX CRM DOW DOV MELI PBF TPRE WP KDMN STZ UTX BKI TWC PVH DVMT FPAC.U GOOGL MSFT APY MHK TPNTF GRBK FB DOV.WI LEN NXPI PYPL NFLX BAX GOOG LEN.B MPC PAGS ADBE SPGI EGN MON ICE SHY CWH EA WYNN ANTM DWDP BID BLK V DHR ANTX
The relief rally in the U.S. Treasury market since last week has led some to believe that bond prices will recover this month after last month's setback. As I'll explain in this commentary, the long-term trend is still down for T-bond prices and the odds still favor higher yields thanks to a stronger economy. However, the bond bulls still have a chance to regain control the short-term trend before the summer is over, for reasons we'll discuss here.
Are you holding a larger than normal allocation of cash these days? Seems like a lot of folks on Seeking Alpha are doing that if the site's contributors and commenters are representative. Have you given much thought to what you’re doing with that cash? Many of us roll it into their broker’s money market fund and don’t give it a lot of thought. Which is convenient and just fine if you’re using it as a brief holding between investments.
For the seventh week in a row, investors were net purchasers of fund assets (including those of conventional funds and ETFs) in general, adding a little more than $29.6 billion for Thomson Reuters Lipper's fund flows week ended June 6, 2018. However, the headline number was misleading. Despite upbeat economic reports and a market rally during the flows week, fund investors were net redeemers of equity funds (-$4.
IJR IJR IWM SCHP SHY SCHR
The U.S. stock market had a great week with all the major indices logging in more than 2% gains — the best week in two months. Notably, the Dow Jones posted seven consecutive days of gains, its largest winning streak since November. A combination of strong earnings, jump in oil prices and mild inflation has renewed confidence in the equity world. Oil prices surged following Trump’s decision to pull the United States out of the Iran nuclear deal.
VB FB QQQ GOOGL AAPL SHY EEM
For the third week in a row, investors were net purchasers of fund assets (including those of conventional funds and ETFs), taking in a little more than $8.2 billion. Despite market gains during the week, fund investors were net redeemers of equity funds (-$231 million) while being net purchasers of money market funds (+$8.2 billion), municipal bond funds (+$167 million), and taxable bond funds (+$86 million) for the fund-flows week ended May 9, 2018.
BRK.A IVV QQQ AAPL IVV SCHO IWM SHY EEM
The fixed income world gained immense investors' love in April amid persistent stock market volatility. This is especially true as bond ETFs accumulated $14.7 billion last month, representing the highest monthly inflows since October 2014, according to data from BlackRock (read: ETF Asset Report for April 2018: Bonds Top). iShares Short Treasury Bond ETF (SHV - Free Report) topped the list of asset creation, pulling in more than $2.
WFC WFCNP FLOT AGG SHV SHY
The month of April was mixed with earnings showing promise and broader markets returning decent returns despite rising yields and trade tensions. Oil has been on an uptrend. Overall, SPDR S&P 500 ETF (SPY - Free Report) gained about 3.5% in a month’s time (as of Apr 27, 2018), SPDR Dow Jones Industrial Average ETF (DIA - Free Report) rose 2.9% while Nasdaq-100-bsed ETF PowerShares QQQ ETF (QQQ - Free Report) jumped 4.
AGG IVV IEMG DIA SPY IVV EFA FLOT SHY IEFA
U.S. Treasury yields have been somewhat seesawing as multiple factors are impacting the markets at the moment. Despite relatively strong economic fundamentals, trade war fears have made investors question their portfolio allocations and reallocate their assets to counter high volatility.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to SHY / iShares 1-3 Year Treasury Bond ETF on message board site Silicon Investor.
as of ET